Literature DB >> 29348202

Molecular characterization of latent GDF8 reveals mechanisms of activation.

Ryan G Walker1, Jason C McCoy1, Magdalena Czepnik1, Melanie J Mills2,3, Adam Hagg4,5, Kelly L Walton4, Thomas R Cotton6, Marko Hyvönen6, Richard T Lee2,3, Paul Gregorevic5,7,8,9, Craig A Harrison10,11, Thomas B Thompson12.   

Abstract

Growth/differentiation factor 8 (GDF8), or myostatin, negatively regulates muscle mass. GDF8 is held in a latent state through interactions with its N-terminal prodomain, much like TGF-β. Using a combination of small-angle X-ray scattering and mutagenesis, we characterized the interactions of GDF8 with its prodomain. Our results show that the prodomain:GDF8 complex can exist in a fully latent state and an activated or "triggered" state where the prodomain remains in complex with the mature domain. However, these states are not reversible, indicating the latent GDF8 is "spring-loaded." Structural analysis shows that the prodomain:GDF8 complex adopts an "open" configuration, distinct from the latency state of TGF-β and more similar to the open state of Activin A and BMP9 (nonlatent complexes). We determined that GDF8 maintains similar features for latency, including the alpha-1 helix and fastener elements, and identified a series of mutations in the prodomain of GDF8 that alleviate latency, including I56E, which does not require activation by the protease Tolloid. In vivo, active GDF8 variants were potent negative regulators of muscle mass, compared with WT GDF8. Collectively, these results help characterize the latency and activation mechanisms of GDF8.

Entities:  

Keywords:  GDF8; GDF8 prodomain; latent activation; myostatin activation; myostatin prodomain

Mesh:

Substances:

Year:  2018        PMID: 29348202      PMCID: PMC5798348          DOI: 10.1073/pnas.1714622115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Henry T Keutmann; Thomas B Thompson
Journal:  Mol Endocrinol       Date:  2012-05-16

2.  Bone morphogenetic protein 1 prodomain specifically binds and regulates signaling by bone morphogenetic proteins 2 and 4.

Authors:  Reema Jasuja; Gaoxiang Ge; Nikolas G Voss; Jamie Lyman-Gingerich; Amanda M Branam; Francisco J Pelegri; Daniel S Greenspan
Journal:  J Biol Chem       Date:  2007-01-25       Impact factor: 5.157

Review 3.  Structural Biology and Evolution of the TGF-β Family.

Authors:  Andrew P Hinck; Thomas D Mueller; Timothy A Springer
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

4.  Development of a small-molecule screening method for inhibitors of cellular response to myostatin and activin A.

Authors:  Jennifer N Cash; Elizabeth B Angerman; R Jason Kirby; Lisa Merck; William L Seibel; Matthew D Wortman; Ruben Papoian; Sandra Nelson; Thomas B Thompson
Journal:  J Biomol Screen       Date:  2013-03-29

5.  GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding.

Authors:  R S Thies; T Chen; M V Davies; K N Tomkinson; A A Pearson; Q A Shakey; N M Wolfman
Journal:  Growth Factors       Date:  2001       Impact factor: 2.511

6.  K153R polymorphism in myostatin gene increases the rate of promyostatin activation by furin.

Authors:  György Szláma; Mária Trexler; László Buday; László Patthy
Journal:  FEBS Lett       Date:  2014-12-25       Impact factor: 4.124

7.  Alternative binding modes identified for growth and differentiation factor-associated serum protein (GASP) family antagonism of myostatin.

Authors:  Ryan G Walker; Elizabeth B Angerman; Chandramohan Kattamuri; Yun-Sil Lee; Se-Jin Lee; Thomas B Thompson
Journal:  J Biol Chem       Date:  2015-02-05       Impact factor: 5.157

8.  FoXS: a web server for rapid computation and fitting of SAXS profiles.

Authors:  Dina Schneidman-Duhovny; Michal Hammel; Andrej Sali
Journal:  Nucleic Acids Res       Date:  2010-05-27       Impact factor: 16.971

9.  Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases.

Authors:  Neil M Wolfman; Alexandra C McPherron; William N Pappano; Monique V Davies; Kening Song; Kathleen N Tomkinson; Jill F Wright; Liz Zhao; Suzanne M Sebald; Daniel S Greenspan; Se-Jin Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

10.  Elevated expression of activins promotes muscle wasting and cachexia.

Authors:  Justin L Chen; Kelly L Walton; Catherine E Winbanks; Kate T Murphy; Rachel E Thomson; Yogeshwar Makanji; Hongwei Qian; Gordon S Lynch; Craig A Harrison; Paul Gregorevic
Journal:  FASEB J       Date:  2013-12-30       Impact factor: 5.191

View more
  18 in total

1.  Structural characterization of an activin class ternary receptor complex reveals a third paradigm for receptor specificity.

Authors:  Erich J Goebel; Richard A Corpina; Cynthia S Hinck; Magdalena Czepnik; Roselyne Castonguay; Rosa Grenha; Angela Boisvert; Gabriella Miklossy; Paul T Fullerton; Martin M Matzuk; Vincent J Idone; Aris N Economides; Ravindra Kumar; Andrew P Hinck; Thomas B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-17       Impact factor: 11.205

2.  Structural biology of the TGFβ family.

Authors:  Erich J Goebel; Kaitlin N Hart; Jason C McCoy; Thomas B Thompson
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-09

3.  Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.

Authors:  Jason C McCoy; Ryan G Walker; Nathan H Murray; Thomas B Thompson
Journal:  J Biol Chem       Date:  2019-02-27       Impact factor: 5.157

4.  Mutations in GDF11 and the extracellular antagonist, Follistatin, as a likely cause of Mendelian forms of orofacial clefting in humans.

Authors:  Timothy C Cox; Andrew C Lidral; Jason C McCoy; Huan Liu; Liza L Cox; Ying Zhu; Ryan D Anderson; Lina M Moreno Uribe; Deepti Anand; Mei Deng; Chika T Richter; Nichole L Nidey; Jennifer M Standley; Elizabeth E Blue; Jessica X Chong; Joshua D Smith; Edwin P Kirk; Hanka Venselaar; Katy N Krahn; Hans van Bokhoven; Huiqing Zhou; Robert A Cornell; Ian A Glass; Michael J Bamshad; Deborah A Nickerson; Jeffrey C Murray; Salil A Lachke; Thomas B Thompson; Michael F Buckley; Tony Roscioli
Journal:  Hum Mutat       Date:  2019-06-18       Impact factor: 4.878

5.  Protection of the Prodomain α1-Helix Correlates with Latency in the Transforming Growth Factor-β Family.

Authors:  Viet Q Le; Roxana E Iacob; Bo Zhao; Yang Su; Yuan Tian; Cameron Toohey; John R Engen; Timothy A Springer
Journal:  J Mol Biol       Date:  2022-01-04       Impact factor: 5.469

6.  Structure of the human myostatin precursor and determinants of growth factor latency.

Authors:  Thomas R Cotton; Gerhard Fischer; Xuelu Wang; Jason C McCoy; Magdalena Czepnik; Thomas B Thompson; Marko Hyvönen
Journal:  EMBO J       Date:  2018-01-12       Impact factor: 11.598

7.  Tolloid cleavage activates latent GDF8 by priming the pro-complex for dissociation.

Authors:  Viet Q Le; Roxana E Iacob; Yuan Tian; William McConaughy; Justin Jackson; Yang Su; Bo Zhao; John R Engen; Michelle Pirruccello-Straub; Timothy A Springer
Journal:  EMBO J       Date:  2018-01-17       Impact factor: 11.598

8.  Characterization of tolloid-mediated cleavage of the GDF8 procomplex.

Authors:  Jason C McCoy; Erich J Goebel; Thomas B Thompson
Journal:  Biochem J       Date:  2021-05-14       Impact factor: 3.857

Review 9.  Structural perspective of BMP ligands and signaling.

Authors:  Gregory R Gipson; Erich J Goebel; Kaitlin N Hart; Emily C Kappes; Chandramohan Kattamuri; Jason C McCoy; Thomas B Thompson
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

10.  Mutational Analysis of the Putative Anti-Müllerian Hormone (AMH) Binding Interface on its Type II Receptor, AMHR2.

Authors:  Kaitlin N Hart; David Pépin; Magdalena Czepnik; Patricia K Donahoe; Thomas B Thompson
Journal:  Endocrinology       Date:  2020-07-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.